Gaps in glucagon fills among commercially insured patients receiving a glucagon prescription

Joseph R. Herges, Jordan D. Haag, Kimberly A. Kosloski-Tarpenning, Kristin C. Mara, Rozalina G. McCoy

Research output: Contribution to journalArticlepeer-review

Abstract

Glucagon is critically underutilized, and we explored whether this is due to inadequate glucagon prescribing or the patient's inability to fill prescriptions. Of 216 commercially insured, high-risk individuals with diabetes who were prescribed glucagon in our healthcare system, 142 (65.4%) had a claim indicating its fill within 30 days.

Original languageEnglish (US)
Article number110720
JournalDiabetes Research and Clinical Practice
Volume200
DOIs
StatePublished - Jun 2023

Keywords

  • Diabetes
  • Glucagon
  • Hypoglycemia

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Gaps in glucagon fills among commercially insured patients receiving a glucagon prescription'. Together they form a unique fingerprint.

Cite this